Search

Your search keyword '"Chunmei Bai"' showing total 285 results

Search Constraints

Start Over You searched for: Author "Chunmei Bai" Remove constraint Author: "Chunmei Bai"
285 results on '"Chunmei Bai"'

Search Results

1. Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial

2. Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival

Catalog

Books, media, physical & digital resources

3. Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

4. Consensus on the clinical diagnosis and treatment of grade 3 pancreatic neuroendocrine tumors

5. Nitric oxide delays the postharvest nutritional quality decline of 'Golden Hook' beans

6. Dissection of mRNA ac4C acetylation modifications in AC and Nr fruits: insights into the regulation of fruit ripening by ethylene

7. Impact of the gut microbiome on response and toxicity to chemotherapy in advanced esophageal cancer

8. Chinese expert consensus on multidisciplinary diagnosis and treatment of pancreatic neuroendocrine liver metastases

9. Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

10. A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

11. Inland populations of sugar maple manifest higher phenological plasticity than coastal populations

12. Impact of antagonist peptides and chelators on the diagnostic performance of PET/CT using gallium-68–labeled somatostatin receptor antagonists

13. Evolving landscape of clinical trials in gastroenteropancreatic neuroendocrine neoplasms in the past two decades

14. Transcriptomics and metabolomics analyses provide insights into postharvest ripening and senescence of tomato fruit under low temperature

15. Necroptosis-related signatures identify two distinct hepatocellular carcinoma subtypes: Implications for predicting drug sensitivity and prognosis

16. Mesenchymal stem cells derived from adipose accelerate the progression of colon cancer by inducing a MT-CAFs phenotype via TRPC3/NF-KB axis

17. Prognostic and predictive significance of circulating biomarkers in patients with advanced upper gastrointestinal cancer undergoing systemic chemotherapy

18. Clinical features and prognosis of lung cancer in patients with connective tissue diseases: a retrospective cohort study

19. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

20. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma

21. Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

22. Transcriptomic, metabolomic, and ATAC-seq analysis reveal the regulatory mechanism of senescence of post-harvest tomato fruit

23. Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

24. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data

25. Regulations of m6A methylation on tomato fruit chilling injury

26. Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

27. Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

28. Mesenchymal stem cells derived from adipose tissue accelerate the progression of colon cancer by inducing a MTCAF phenotype via ICAM1/STAT3/AKT axis

29. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma

30. The role of PKM2 nuclear translocation in the constant activation of the NF-κB signaling pathway in cancer-associated fibroblasts

31. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

32. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)

33. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

34. Extracellular Matrix-Based Gene Expression Signature Defines Two Prognostic Subtypes of Hepatocellular Carcinoma With Different Immune Microenvironment Characteristics

35. Characteristics and Prognostic Nomogram for Primary Lung Lepidic Adenocarcinoma

36. Revealing the Specific Regulations of Brassinolide on Tomato Fruit Chilling Injury by Integrated Multi-Omics

37. The Relationship Between Gut Microbiome Features and Chemotherapy Response in Gastrointestinal Cancer

38. Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer

39. Dependence Analysis of PM2.5 Concentrations in 295 Chinese Cities in the Winter of 2019–2020

40. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection

41. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

42. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma

43. microRNA‐222 promotes colorectal cancer cell migration and invasion by targeting MST3

44. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

45. Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer

46. The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

47. Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review

48. Influenza in hospitalised patients with malignancy: a propensity score matching analysis

49. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis

50. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review